Medicxi
Signal active
Investment Firm
Overview
Medicxi is an investment firm that focuses on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.
Highlights
Founded
2016
Industry
Venture Capital
Employees
11-50
Investment
46
Lead Investment
29
Exits
13
Stages
Early Stage Venture, Seed, Late Stage Venture, Private Equity
Investor Type
Venture Capital
Location
Europe
Contact Information
Social
Profile Resume
Medicxi, established in 2016 and headquartered in Europe., specializes in Early Stage Venture, Seed, Late Stage Venture, Private Equity investments across Biotechnology, Health Care, Pharmaceutical, Information Technology, Software, Financial Services, Venture Capital, Finance, CleanTech, Manufacturing. The organization boasts a portfolio of 46 investments, with an average round size of $47.2M and 13 successful exits. Their recent investments include Capella BioScience, OUP (Osage University Partners), DCVC, Advent Life Sciences, Gadeta. The highest investment round they participated in was $166.1B. Among their most notable exits are Capella BioScience and OUP (Osage University Partners). Explore their portfolio in detail, see who is connected to them, and find their contact information on our platform.
Investment portfolio
Medicxi has made 46 investments. Their most recent investment was on Apr 08, 2024, when D3 Bio raised $62.0M.
Medicxi has made 7 diversity investments. Their most recent diversity investment was on Jun 10, 2021, when Kurome Therapeutics raised $15.0M.
investments
46
Diversity investments
7
Lead investments
29
Number of exits
13
Investments
46
| Annouced Date | Organization Name | Industry | Money Raised |
|---|---|---|---|
| Aug 23, 2023 | Fore Biotherapeutics | Biotechnology | 75.0M |
| Feb 12, 2024 | Alys Pharmaceuticals | Biotechnology | 100.0M |
| Feb 13, 2024 | ProfoundBio | Biotechnology | 112.0M |
| Apr 08, 2024 | D3 Bio | Biotechnology | 62.0M |
Exits
13
Funding Timeline
Funding rounds
46
Investors
0
Funds
5
Funding Rounds
46
Medicxi has raised 46 rounds. Their latest funding was raised on Apr 08, 2024 from a Series A - D3 Bio round.
| Annouced Date | Transaction Name | Number of Investors | Money Raised | Lead Investor |
|---|---|---|---|---|
| Aug 23, 2023 | Series D - Fore Biotherapeutics | - | 75.0M | - |
| Feb 12, 2024 | Seed Round - Alys Pharmaceuticals | - | 100.0M | - |
| Feb 13, 2024 | Series B - ProfoundBio | - | 112.0M | - |
| Apr 08, 2024 | Series A - D3 Bio | - | 62.0M | - |
Investors
0
There is no funding round available on this profile
Fund raised
2
Susa Ventures has raised a total of $590M across 6 funds, their latest being Susa Ventures Opportunities II. This fund was announced on Aug 30, 2021 and raised a total of $250M.
| Annouced Date | Fund Name | Money Raised |
|---|---|---|
| May 10, 2013 | OTPPLESS | 1.0M |
| May 11, 2013 | OTPPLESS | 1.0M |
Invest in industries
Recent Activity
There is no recent news or activity for this profile.